BING Z CARTER to Mice
This is a "connection" page, showing publications BING Z CARTER has written about Mice.
Connection Strength
0.574
-
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
Score: 0.051
-
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica. 2023 09 01; 108(9):2513-2519.
Score: 0.051
-
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 04 24; 13(1):57.
Score: 0.049
-
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
Score: 0.046
-
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022 01 01; 107(1):58-76.
Score: 0.045
-
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood. 2021 10 28; 138(17):1637-1641.
Score: 0.044
-
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Mol Cancer Ther. 2020 08; 19(8):1636-1648.
Score: 0.040
-
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. 2020 05; 105(5):1274-1284.
Score: 0.038
-
An ARC-Regulated IL1?/Cox-2/PGE2/?-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res. 2019 03 15; 79(6):1165-1177.
Score: 0.037
-
Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
Score: 0.034
-
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67.
Score: 0.030
-
Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010 Jan 14; 115(2):306-14.
Score: 0.019
-
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9.
Score: 0.016
-
Bcl-2 inhibition combined with PPARa activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Death Dis. 2023 08 29; 14(8):573.
Score: 0.013
-
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
Score: 0.012
-
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. J Transl Med. 2021 03 21; 19(1):117.
Score: 0.011
-
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673.
Score: 0.010
-
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis. 2016 09 22; 7(9):e2371.
Score: 0.008
-
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget. 2014 Oct 15; 5(19):9118-32.
Score: 0.007
-
Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 01; 116(21):4980-90.
Score: 0.005
-
Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther. 2008 May; 16(5):886-92.
Score: 0.004
-
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77.
Score: 0.004